Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36027558

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2022 Oct 10
First author
Rugo HS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Feb 1;41(4):732-735. doi: 10.1200/JCO.22.02217.
    note
    Source null
    related pmid
    36446052
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2023 Mar 10;41(8):1630. doi: 10.1200/JCO.22.01961.
    note
    Source null
    related pmid
    36608300
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2023 Mar 10;41(8):1631. doi: 10.1200/JCO.22.02113.
    note
    Source null
    related pmid
    36608301
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2023 Mar 10;41(8):1629-1630. doi: 10.1200/JCO.22.02234.
    note
    Source null
    related pmid
    36608304
    relationship
    Comment in
  5. citation
    Ann Transl Med. 2023 Jan 15;11(1):27. doi: 10.21037/atm-22-5266.
    note
    Source null
    related pmid
    36760255
    relationship
    Comment in
  6. citation
    Ann Transl Med. 2023 Mar 15;11(5):228. doi: 10.21037/atm-22-6266.
    note
    Source null
    related pmid
    37007548
    relationship
    Comment in
  7. citation
    Ann Transl Med. 2023 Mar 31;11(6):269. doi: 10.21037/atm-23-41.
    note
    Source null
    related pmid
    37082695
    relationship
    Comment in
  8. citation
    Ann Transl Med. 2023 Oct 25;11(11):399. doi: 10.21037/atm-23-314.
    note
    Source null
    related pmid
    37970594
    relationship
    Comment in

Authors and identifiers

  1. name
    Rugo HS
    type
    Author
  2. name
    Bardia A
    type
    Author
  3. name
    Marmé F
    type
    Author
  4. name
    Cortes J
    type
    Author
  5. name
    Schmid P
    type
    Author
  6. name
    Loirat D
    type
    Author
  7. name
    Trédan O
    type
    Author
  8. name
    Ciruelos E
    type
    Author
  9. name
    Dalenc F
    type
    Author
  10. name
    Pardo PG
    type
    Author
  11. name
    Jhaveri KL
    type
    Author
  12. name
    Delaney R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Rugo HS
    type
    Author
  2. name
    Bardia A
    type
    Author
  3. name
    Marmé F
    type
    Author
  4. name
    Cortes J
    type
    Author
  5. name
    Schmid P
    type
    Author
  6. name
    Loirat D
    type
    Author
  7. name
    Trédan O
    type
    Author
  8. name
    Ciruelos E
    type
    Author
  9. name
    Dalenc F
    type
    Author
  10. name
    Pardo PG
    type
    Author
  11. name
    Jhaveri KL
    type
    Author
  12. name
    Delaney R
    type
    Author
bibliography ids
  1. nci-bib-f29ac6e086edaace2b16fb86
book metadata
content sha256
51f4833ddb4faebce387939742609ccedeb5b9434ad9fefb8e861c4d81aef328
document type
citation
dois
  1. 10.1200/JCO.22.01002
electronic publication date
display
2022 Aug 26
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36027558
immutable id
pubmed:36027558@51f4833ddb4faebce387939742609ccedeb5b9434ad9fefb8e861c4d81aef328
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
29
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3365-3376
volume
40
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2023 Feb 1;41(4):732-735. doi: 10.1200/JCO.22.02217.
    note
    Source null
    related pmid
    36446052
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2023 Mar 10;41(8):1630. doi: 10.1200/JCO.22.01961.
    note
    Source null
    related pmid
    36608300
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2023 Mar 10;41(8):1631. doi: 10.1200/JCO.22.02113.
    note
    Source null
    related pmid
    36608301
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2023 Mar 10;41(8):1629-1630. doi: 10.1200/JCO.22.02234.
    note
    Source null
    related pmid
    36608304
    relationship
    Comment in
  5. citation
    Ann Transl Med. 2023 Jan 15;11(1):27. doi: 10.21037/atm-22-5266.
    note
    Source null
    related pmid
    36760255
    relationship
    Comment in
  6. citation
    Ann Transl Med. 2023 Mar 15;11(5):228. doi: 10.21037/atm-22-6266.
    note
    Source null
    related pmid
    37007548
    relationship
    Comment in
  7. citation
    Ann Transl Med. 2023 Mar 31;11(6):269. doi: 10.21037/atm-23-41.
    note
    Source null
    related pmid
    37082695
    relationship
    Comment in
  8. citation
    Ann Transl Med. 2023 Oct 25;11(11):399. doi: 10.21037/atm-23-314.
    note
    Source null
    related pmid
    37970594
    relationship
    Comment in
outcomes validated
false
pmid
36027558
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
9b66330c6b3e2249ee925d3d710de1777474e805cfb4bef2e45568b93ab88aca
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Oct 10
precision
day
year
2022
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36027558/
title
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Preserved source evidence · Not medical advice